Curis vs TScan Therapeutics
CRIS and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and TCRX compare
TScan Therapeutics is the larger company, worth 9.0 times as much as Curis ($10.2M against $1.1M).
TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −62.2% for Curis).
Curis keeps more of each dollar of sales as profit, with a net margin of −490% compared with −1655% at TScan Therapeutics.
Curis scores higher on the StockData Score (7 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $1.1M | $10.2M |
| Share price | $0.542 | $0.151 |
| Change, 1 year | −98.0% | −86.3% |
| Change, 5 years | −100.0% | −98.3% |
| Beta (5Y) | −0.10 | 2.15 |
| Employees | 24 | 142 |
| StockData Score | ||
| Total score | 7 (better) | 4 |
| Valuation score | 3 | 3 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 1.4× |
| P/B | 0.2× | 0.1× (better) |
| FCF yield | – | −1157% |
| Fair value | $6.75 | $1.36 |
| Margin of safety | 92.0% (better) | 88.9% |
| Growth | ||
| Revenue growth (TTM) | −62.2% | 2.2% (better) |
| Revenue growth, 5Y average | −2.7% | 56.9% (better) |
| Profitability | ||
| Operating margin | −203% (better) | −1695% |
| Net margin | −490% (better) | −1655% |
| FCF margin | – | −1666% |
| Return on equity | – | −95.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.47 (better) |
| Interest coverage | – | −43.2× |
| Current ratio | 0.49 | 3.37 (better) |
| Altman Z-score | −96.17 | −6.31 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −2171% | – |
| Shareholder yield | −2171% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 32.1% | 53.5% |
| Held by insiders | 20.4% | 32.8% |
| Insider net buying, 12 months | $5.5K | $146K (better) |
| Short interest, % of float | 61.8% | 4.4% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.